The latest market report published by Credence
Research, Inc. “Photopheresis
Products Market By Type (Closed System, Open System), By
Therapeutic Area (Cutaneous T-Cell Lymphoma, Solid Organ Transplant Rejections,
Autoimmune Diseases, Graft Versus Host Diseases) - Growth, Future Prospects,
Competitive Analysis, 2018 - 2026,” The global market for photopheresis
Products was valued at US$ 257 million in 2017 and is expected to reach US$
418.56 million by 2026, increasing to CAGR by 5.5 per cent from 2018 to 2026.
Market
Insights
Photopheresis uses apheresis and photodynamic therapy
to treat blood with a photosensitizing agent followed by treatment with defined
wavelengths of light. In photopheresis, buffy coat (WBC and platelets) is
separated from the whole blood and then chemically handled
with8-methoxypsoralene and subjected to ultraviolet-A light. As the incidence
of autoimmune diseases, ongoing research and development activities are being
conducted to develop the most suitable treatments. Photopheresis is also seen
as a promising therapy for transplant rejection, graft versus host disease,
cutaneous T-cell lymphoma, and autoimmune illnesses.
Browse
the full report at https://www.credenceresearch.com/report/photopheresis-market
Based on product kinds, the worldwide market for
photopheresis products is segmented into closed systems and open systems. In
2017, the closed systems segment retained the biggest market share owing to its
advanced technology and the increasing preference of patients and physicians
for the use of closed systems for photopheresis treatment. The popularity of
closed systems is also ascribed to their flexible use in all the therapeutic
fields considered.
Among the therapeutic fields considered, i.e.
autoimmune illnesses, graft versus host illness, cutaneous T-cell lymphoma and
strong organ transplant rejection, photopheresis has the greatest application
in autoimmune diseases. Graft versus host disease was identified as the biggest
segment in 2017 owing to variables such as increasing allogeneic
transplantation, a big number of chronic graft versus host disease patients,
the evolution of diagnostic techniques and a consistent increase in research
and development attempts.
Geographically, North America is the largest
regional market for photopheresis. Presence of large pool of autoimmune disease
patients, greater awareness in general population, well-structured
reimbursement scenario and widespread presence of market incumbents contribute
to the dominant position of North America. On the other hand, Asia Pacific is
estimated to be the fastest progressing market for photopheresis. Rapidly
developing healthcare infrastructure, significantly large patient pool and
improving diagnostics front are the key growth drivers of Asia Pacific market.
Download
Free PDF Sample Request: https://www.credenceresearch.com/sample-request/58735
The global photopheresis market is highly
competitive and diversified, characterized by the presence of large number of
players. The domination of the key players is subject to their product
diversity and core competencies. Some of the major players operating in the
global photopheresis market are Terumo Corporation, Malinckrodt
Pharmaceuticals, Fresenius Kabi AG, Macopharma, Haemonetics Corporation, and
others.
Key Market Movements:
- High prevalence of autoimmune diseases, and growing number of transplants, supported by evolved diagnostics technologies
- Increasing
awareness about benefits of apheresis and photopheresis
- Improving
reimbursement for autoimmune diseases and organ transplantations
- Evolving
medical tourism industry in Asia Pacific and Latin America
By Type (2016–2026; US$ Mn)
- Closed
System
- Open
System
By Therapeutic Area (2016–2026; US$ Mn)
- Cutaneous
T-cell Lymphoma
- Solid
Organ Transplant Rejections
- Autoimmune
Diseases
- Graft
Versus Host Diseases
By Geography Segment
- North
America
- Europe
- Asia
Pacific (APAC)
- Middle
East & Africa (MEA)
- Latin
America
No comments:
Post a Comment